openPR Logo
Press release

Global Cancer Vaccines Market Sales Revenue Clinical Trials Pipeline Report

07-04-2017 07:14 AM CET | Health & Medicine

Press release from: Kuick Resarch

Global Cancer Vaccines Market Sales Revenue Clinical Trials

Cancer vaccines are a viable option for treating many types of cancers which in the present day do not have effective treatments. Therapeutic cancer vaccines and Prophylactic cancer vaccines are the two broad segments into which the cancer vaccines market is categorized. Therapeutic or Treatment vaccines are targeted at treating an existing cancer by strengthening the body’s natural defences against the cancer and the Prophylactic or Preventive vaccines are used to prevent cancer from developing in healthy people. With the approval of the expensive prostate cancer vaccine, Provenge by Dendreon, the field of cancer vaccines has received an unprecedented boost. Consequently, many companies are expected to enter this emerging and highly profitable field of preventing, treating, and potentially curing cancer.

Download Report:

https://www.kuickresearch.com/report-Global-Cancer-Vaccines-Market-&-Pipeline-Analysis.php

For Report Sample Contact: neeraj@kuickresearch.com or +91-11-47067990

"Global Cancer Vaccines Market & Pipeline Analysis"
Table of Contents

1. Introduction to Cancer Vaccines

2. Cancer Vaccines: Mechanism & Innovations
2.1 Idiotype Cancer Vaccine Mechanism
2.2 Cellular Cancer Vaccines Mechanism
2.3 Ganglioside Antigens based Cancer Vaccines Mechanism
2.4 Peptide Cancer Vaccine Mechanism
2.5 Tumor Host Interaction Cancer Vaccine Mechanism

3. Adjuvants Platforms for Cancer Vaccines Delivery

4. Global Cancer Vaccines Market Overview
4.1 Current Market Scenario
4.2 Clinical Pipeline Overview

5. Personalized Cancer Vaccines: Progress & Possibilities

6. Public HPV Cancer Vaccination Program

7. Global Cancer Vaccines Market Dynamics
7.1 Favorable Market Parameters
7.1.1 Increasing Demand for Cancer Vaccines
7.1.2 Government Funding & Support
7.1.3 Innovative Technologies for Cancer Vaccine Development
7.1.4 On Demand Personalized Cancer Vaccines
7.1.5 Myriad of Demographs for Cancer Vaccine Development
7.2 Issues to be Resolved

8. Future Prospects of Cancer Vaccines

9. Global Cancer Vaccines Clinical Pipeline Insight by Phase, Indication, Company & Country
9.1 Phase: Unknown
9.2 Phase: Research
9.3 Phase: Preclinical
9.4 Phase: Clinical
9.5 Phase-I
9.6 Phase-I/II
9.7 Phase-II
9.8 Phase-II/III
9.9 Phase-III
9.10 Phase-Preregistration
9.11 Phase-Registered

10. Marketed Cancer Vaccines Clinical Insight by Indication, Company & Country

11. Suspended & Discontinued Cancer Vaccines Clinical Pipeline by Phase, Indication, Company & Country
11.1 No Development Reported
11.2 Discontinued
11.3 Suspended

12. FDA Regulatory Framework for Cancer Vaccines Development & Marketing
12.1 Considerations for both Early and Late Phase Clinical Trials
12.1.1 Patient Population
12.1.2 Monitoring the Immune Response
12.1.3 Biomarkers as Evidence of Efficacy
12.1.4 Adjuvants Used To Stimulate Immune Response
12.1.5 Multi-Antigen Vaccines
12.1.6 Disease Progression/Recurrence Immediately or Shortly After The Initial Administration Of Cancer Vaccines
12.1.7 Concomitant & Subsequent Therapies
12.2 Considerations for Early Phase Clinical Trials
12.2.1 Starting Dose & Dosing Schedule
12.2.2 Booster & Maintenance Therapy
12.2.3 Dose Escalation
12.2.4 Single Arm Versus Randomized Phase 2 Trials In Early Development
12.3 Considerations for Late Phase Clinical Trials
12.3.1 Safety Profile from Early Phase Clinical Trials
12.3.2 Endpoints
12.3.3 Statistical Issues
12.3.4 Control Issues
12.3.5 Delayed Vaccine Effect
12.3.6 Autologous Vaccine Trials
12.3.7 Accelerated Approval Regulations

13. Competitive Landscape: Business Overview & Product Pipeline
13.1 Advaxis
13.2 Celldex Therapeutics
13.3 Dendreon Corporation
13.4 Galena Biopharma
13.5 ImmunoCellular Therapeutics
13.6 ImmunoGen
13.7 Inovio Pharmaceuticals
13.8 Merck
13.9 NeoStem Oncology
13.10 NewLink Genetics
13.11 Northwest Biotherapeutics
13.12 Novartis
13.13 Peregrine Pharmaceuticals
13.14 Roche
13.15 Seattle Genetics

Figure 1-1: Categorization & Function of Cancer Vaccines
Figure 2-1: Classification of Different Types of Cancer vaccines

Figure 4-1: Global Cancer Vaccines Market (US$ Billion), 2014-2020
Figure 4-2: Global Cancer Vaccines Market by Region (%), 2014 & 2020
Figure 4-3: Examples of Commercially Available Cancer Vaccines

Figure 4-4: Global Cancer Vaccines Clinical Pipeline by Phase (%), 2014
Figure 4-5: Global Cancer Vaccines Clinical Pipeline by Phase (Number), 2014
Figure 4-6: No Development Reported in Cancer Vaccines Pipeline by Phase (%), 2014
Figure 4-7: No Development Reported in Cancer Vaccines Pipeline by Phase (Number), 2014
Figure 4-8: Discontinued Cancer Vaccines in Pipeline by Phase (%), 2014
Figure 4-9: Discontinued Cancer Vaccines in Pipeline by Phase (Number), 2014
Figure 4-10: Suspended Cancer Vaccines in Pipeline by Phase (%), 2014
Figure 4-11: Suspended Cancer Vaccines in Pipeline by Phase (Number), 2014

Figure 5-1: Overview of Personalized Cancer Vaccines Development
Figure 5-2: Methodology for the Development of Personalized Cancer Vaccine
Figure 5-3: Schematic Representation of Development of Skin Implant for Cancer Vaccine
Figure 6-1: Prophylactic Cancer Vaccines Available for Different Serotypes of HPV
Figure 7-1: Factors Responsible for High Demand of Cancer Vaccines

Figure 13-1: Advaxis Clinical Pipeline
Figure 13-2: Celldex Therapeutics Clinical Pipeline
Figure 13-3: Galena Biopharma Clinical Pipeline
Figure 13-4: ImmunoCellular Therapeutics Clinical Pipeline
Figure 13-5: ImmunoGen Clinical Pipeline
Figure 13-6: Inovio Pharmaceuticals Clinical Pipeline
Figure 13-7: NewLink Genetics Corporation Clinical Pipeline
Figure 13-8: Northwest Biotherapeutics Clinical Pipeline
Figure 13-9: Peregrine Pharmaceuticals Clinical Pipeline
Figure 13-10: Seattle Genetics Clinical Pipeline

Table 5-1: Different Types of Biomarkers for Personalized Cancer Vaccine Development

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
Avanta Business Center 4th Floor,
Statesman House Barakhamba Road,
Connaught Place New Delhi – 110 001, India
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Global Cancer Vaccines Market Sales Revenue Clinical Trials Pipeline Report here

News-ID: 606812 • Views:

More Releases from Kuick Resarch

Lumakras Drug Clinical Insight and Sales Forecast 2026
Lumakras Drug Clinical Insight and Sales Forecast 2026
"Lumakras Drug Clinical Insight and Sales Forecast 2026" Report Highlights: * NSCLC Targeting Lumakras Market Opportunity (US$ Million) * Colorectal Cancer Targeting Lumakras Market Opportunity (US$ Million) * Pharmacokinetics of Lumakras (Sotorasib) * Dosage, Patent and Price Analysis * Lumakras Ongoing Clinical Trials * Global KRAS Protein Inhibitors Clinical Trials Download Report: https://www.kuickresearch.com/report-lumakras-sotorasib-sales-forecast-fda-approved-kras-inhibitor-clinical-trials-non-small-cell-lung-cancer-nslc-g12c-mutation-c30h30f2n6o3-ras-gtpase The rising burden of cancer and the increasing cancer mortality rates possesses an unmet need for the development of novel therapies in the management
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026
"Global EZH2 Inhibitor Market Opportunity, Sales and Clinical Trials Insight 2026" Report Highlights: * Global EZH2 Inhibitor Market Opportunity > US$ 1.2 Billion by 2026 * Tazverik (Tazemetostat) First Approved EZH2 Inhibitor Drug * Dosage, Price and Sales Analysis of Tazverik * Tazverik Sales Opportunity > US$ 900 Million by 2026 * Tazverik Sales Forecast 2021 Till 2026 * EZH2 Inhibitor Clinical Pipeline Overview By Company, Indication and Phase * EZH2 Inhibitor in Clinical Trials: 7 Drugs Download
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028
Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Tr …
"Global Bispecific Antibody Market Opportunity, Drug Sales, Price and Clinical Trials Insight 2028" Report Highlights: * Global Bispecific Antibody Market Opportunity: > US$ 20 Billion * Global Bispecific Antibody Market Growth Rate: 100% CAGR (2016 -2021) * Approved Bispecific Antibodies In Market: 4 Antibodies * Detailed Market Sales and Trends Insight Till 2028 * Quarterly and Yearly Sales Insight Of Approved Antibodies Till Q1 2022 * Global and Regional Market Analysis * Approved Drug Sales
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026
Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and C …
"Global Fibroblast Growth Factor Receptor Inhibitor Drug Market Opportunity and Clinical Trials Insight 2026" Report Highlights: * Global FGFR Inhibitors Market Opportunity: > USD 4 Billion by 2026 * Role of FGFR Inhibitors in Cancer Therapy * Global FGFR Market Assessment (US$) by Region and Cancer Type Clinical and Sales Insight on Approved FGFR Inhibitors: 3 (Belvesra, Pemazyre and Truseltiq) * Dosage and Drug Price Insight on Approved FGFR Inhibitors * Comprehensive Clinical Trials Insight

All 5 Releases


More Releases for Cancer

Cancer Therapeutics Market New Business Opportunities to Hit $180.19 billion by …
Surge in geriatric population and rise in the number of collaborations & partnerships to facilitate drug development are the key drivers of the global cancer therapeutics market. In addition, heavy inflow of investment in R&D activities has enhanced the development of cancer therapeutics. Furthermore, favorable government regulations for cancer therapeutics and surge in cancer prevalence boost the market. The high demand for personalized medicine along with high potential of emerging
Global Cancer Diagnostics Market Size, Trends & Growth Opportunity By Applicatio …
Cancer diagnostics is a process of detecting various proteins, biomarkers and certain symptoms that result in the detection of presence of cancerous tumour in patients. Detection of certain proteins and biomarkers which are prevalent in cancer disorder thereby results in diagnosis process. Cancer diagnostics includes usage of certain technology and devices for detection purpose. Increase in incidence of target diseases like cancer is key driving factor which is expected to boost
Oncology Nutrition Market led to an unprecedented rise by 2025 : liver cancer, p …
Global Oncology Nutrition Market: Overview Cancer diagnosis creates myriad questions about diet and nutrition. Those pertain to if the food will make a patient feel sick to what should be ingested to fight cancer. This has spawned the oncology nutrition market which has been rising steadily due to the increasing cases of different types of cancer worldwide. During cancer treatment one needs to eat right in order to build up strength
Cancer Immunotherapy Market 2018 To 2025 - SWOT Analysis By Global Industry Reve …
The Cancer Immunotherapy Market research report provided by Crystal Market Research (CMR) is the most detailed study about Cancer Immunotherapy Market that is estimated to grow at a tremendous rate over the forecast period 2018-2025. This report contains precise and updated insights in respect with the leading market players and prevailing regions of the business. Cancer Immunotherapy Market By Product and Cancer Type - Global Industry Analysis And Forecast To 2025:
Oncology Nutrition Market by Cancer Type Breast Cancer, Liver Cancer, Lung Cance …
Lunch of new products for nutrition of oncology patients is expected to drive the oncology nutrition market growth. For instance, in 2016, Hormel Food Corporation, a U.S-based meat food products company, launched a line of packaged ready-to-eat meals for cancer patients, which are called as Hormel Vital Cuisine. These meals consist of carbohydrates, proteins, and fats to help patients fight loss of muscle mass and energy during cancer treatment. Thus launch
Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, C …
Researchmoz added Most up-to-date research on "Cancer Diagnostics Global Market: By Application - Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma & Other Cancers" to its huge collection of research reports. This report studies Cancer Diagnostics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these regions, from 2012 to 2016, and forecast to 2022. This report focuses on top